This SBIR Phase II proposal elaborates on the success achieved during Phase I where IsoSciences was successful in developing synthetic methods for 1) The regioselective preparation of 2 and 4-methoxy-[13C,2H3] labeled estrogens and 2) The preparation of testosterone-[1,2,3-13C3]. The methodology developed in Phase I will be scaled up in Phase II such that IsoSciences, LLC will produce 100mg quantities of several stable-isotope labeled key steroid hormones including 2-, 3-, and 4-methoxyestrogens, estriol, testosterone, estrone, estradiol, and androstenedione and dehydroepiandrosterone. The selected compounds are believed to play critical roles in various cancers and thus have the potential to serve as cancer biomarkers. A significant stumbling block in the research area has been the lack of availability of stable isotope labeled standards for use in detecting and quantifying these key steroids. This Phase II contract will address that significant problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research – Phase II (N44)
Project #
261200900009C-1-0-1
Application #
7976629
Study Section
Project Start
2009-03-01
Project End
2011-02-28
Budget Start
Budget End
Support Year
Fiscal Year
2009
Total Cost
$709,997
Indirect Cost
Name
Isosciences, LLC
Department
Type
DUNS #
City
King of Prussia
State
PA
Country
United States
Zip Code
19406